CAS 141368-69-6
:H-GLY-ILE-LEU-GLY-PHE-VAL-PHE-THR-LEU-OH
- Matrix Protein M1 (58-66) (Influenza A Virus)
- H2N-Gilgfvftl-Oh
- Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu
- Influenza Matrix Peptide
- Influenza Matrix Protein M1 (58-66)
- Influenza Virus Matrix Protein (58-66)
- Gilgfvftl
Matrix Protein M1 (58-66) (Influenza A virus)
CAS :Bachem ID: 4095875.
Formule :C49H75N9O11Degré de pureté :96.8%Couleur et forme :White LyophilisateMasse moléculaire :966.19CEF1, Influenza Matrix Protein M1 (58-66)
CAS :CEF1, M1 (58-66) epitope from influenza A; GILGFVFTL is HLA-A2-restricted.Formule :C49H75N9O11Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :966.17Flu mp 58
CAS :Portion of Influenza MFormule :C49H75N9O11Couleur et forme :PowderMasse moléculaire :966.18 g/molMatrix Protein M1 (58-66) (Influenza A virus) acetate salt
CAS :Please enquire for more information about Matrix Protein M1 (58-66) (Influenza A virus) acetate salt including the price, delivery time and more detailed product information at the technical inquiry form on this pageFormule :C49H75N9O11Degré de pureté :Min. 95%Masse moléculaire :966.17 g/molH-GILGFVFTL-OH
CAS :FluM1 (58-66) is a short part of the matrix protein of Influenza A virus which is the most abundant component of this enveloped virus localized under the viral lipid envelope. The GILGFVFTL epitope is highly conserved in Influenza A virus strains at a rate of 93% for 69 strains tested. Human Influenza epitopes may bind MHC molecules and then may be recognized by CD8+ cytotoxic T cells. Applications of FluM1 (58-66): FluM1 (58-66) is used to stimulate CTL responses in peripheral blood mononuclear cells (PBMCs). Then, ELISPOT assay is used to quantify peptide epitope specificity and IFN-γ releasing effector cells. FluM1 (58-66) has shown CTL responses qualified of immunodominant with restriction by HLA-A*02:01. It has also been detected CTL responses when FluM1 (58-66) is restricted by all HLA-C. Therefore, FluM1 (58-66) may help to understand the reaction of immune system against Influenza virus of each populations having different HLA type. FluM1 (58-66) has indeed prompted research to develop T-cell vaccine strategies capable of inducing specific CTL responses in patients upon immunization with Influenza M1 antigenic epitope. MVA-NP+M1 vaccine use GILGFVFTL epitope and is tested in clinical trial. Potential cross-reactivity with HIV-1 p17 Gag (77-85): Moreover, FluM1 (58-66) share similarities with HIV-1 p17 Gag (77-85) which can potentially show a cross-reactivity between these epitopes. It has been demonstrated a cross-reactivity and results suggest that immunity following infection by Influenza virus causes specific immune response to HIV-1 p17 Gag (77-85).
Formule :C49H75N9O11Masse moléculaire :966.18 g/mol


